Kubra Sarici

Kubra Sarici

Auto-generated profile, based on publicly available information

Kubra Sarici

Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Ophthalmology Retina
Verified
Journal Article
Open access
Justis P. EhlersJustis P. Ehlers
Justis P. Ehlers
LLLeina Lunasco
Leina Lunasco
SYSari Yordi
Sari Yordi
HCHasan Cetin
Hasan Cetin
TLThuy K. Le
Thuy K. Le
SSSunil K. Srivastava
Sunil K. Srivastava

1 February 2023 in Ophthalmology Retina
Verified
Journal Article
Open access
KSKubra Sarici
Kubra Sarici
SYSari Yordi
Sari Yordi
AMAlison Martin
Alison Martin
LLLeina Lunasco
Leina Lunasco
CMChristopher Mugnaini
Christopher Mugnaini
Justis P. EhlersJustis P. Ehlers
Justis P. Ehlers
The purpose of this study was to evaluate the longitudinal change in quantitative ultrawide-field angiographic (UWFA) parameters and correlate them with functional outcomes and spectral domain-OCT metrics. This study is a post hoc analysis of the phase II RUBY study: a prospective, randomized trial of patients with diabetic macular edema (DME) treated with either intravitreal aflibercept injection (IAI) or combined IAI/nesvacumab (antiangiopoietin 2 mAb). Subjects with DME that underwent UWFA across all treatment groups (n = 44). A machine learning-enabled feature extraction system generated panretinal quantitative UWFA metrics, including leakage, ischemia, and microaneurysm (MA) burden. Zonal assessments were performed corresponding to the macula, midperiphery, and far periphery. Changes in ischemic area and index (proportion of nonperfusion in analyzable retina), leakage area and index (proportion of leakage in analyzable retina), and MA count at baseline, week 12, week 24, and week 36 were analyzed. Spectral-domain-OCT quantitative metrics, such as central subfield thickness, ellipsoid zone (EZ) integrity parameters, intraretinal fluid (IRF) volume, and subretinal fluid (SRF) volume were extracted via a machine learning-enhanced OCT feature extraction platform and analyzed. Additionally, the effect of these changes on best-corrected visual acuity (BCVA) was evaluated. Mean panretinal leakage index, zonal leakage area, and panretinal MA count improved significantly between baseline and week 36. Panretinal ischemic index decreased between baseline and week 36, with some aspects showing significant improvement. Mean BCVA significantly improved from baseline to week 36. There was a significant inverse correlation between change in BCVA and change in macular leakage area. A direct correlation was observed between both baseline macular leakage area and panretinal leakage index with IRF volume, SRF volume, and EZ disruption on OCT. Assessment of UWFA parameters demonstrates a significant improvement in panretinal leakage index, leakage area, and MA burden in eyes treated with IAI with or without nesvacumab. A numeric reduction in panretinal ischemic index and area was noted. The analysis also shows the critical association of leakage with visual and OCT features. This highlights the potential role of UWFA in disease burden assessment, with leakage parameters serving as a primary end point. Proprietary or commercial disclosure may be found after the references.

1 October 2018 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
AOAbdullah Ozkaya
Abdullah Ozkaya
LKLevent Karabaş
Levent Karabaş
CACengiz Alagöz
Cengiz Alagöz
ZAZeynep Alkın
Zeynep Alkın
ÖAÖzgür Artunay
Özgür Artunay
ZYZeynep Yılmazabdurrahmanoğlu
Zeynep Yılmazabdurrahmanoğlu
Objectives: To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients. Materials and Methods: Multicenter, retrospective, interventional, non-comparative study. The records of nAMD patients treated with an anti-VEGF agent on a pro re nata treatment regimen basis between January 2013 and December 2015 were reviewed. The patients who completed a follow-up period of 12 months were included. Primary outcome measures of this study were the visit and injection numbers during the first year. Results: Eight hundred eighty eyes of 783 patients met the inclusion criteria for the study. Mean number of visits at month 12 was 6.9 +/- 2.5 (range: 1-15). Mean number of injections at month 12 was 4.1 +/- 1.9 (range: 1-11). Mean visual acuity at baseline and months 3, 6, and 12 was 0.90 +/- 0.63 LogMAR (range: 0.0-3.0), 0.79 +/- 0.57 LogMAR (range: 0.0-3.0), 0.76 +/- 0.57 LogMAR (range: 0.0-3.0), and 0.79 +/- 0.59 LogMAR (range: 0.0-3.0), respectively. Mean central retinal thickness at baseline and months 6 and 12 was 395 +/- 153 mu m (range: 91-1582), 330 +/- 115 mu m (range: 99-975), and 332 +/- 114 mu m (range: 106-1191), respectively. Conclusion: The numbers of visits and injections were much lower than ideal and were insufficient with the pro re nata treatment regimen.

8 March 2024 in Ophthalmology Retina
Verified
Journal Article
Closed access
GNGrace E. Nipp
Grace E. Nipp
KSKubra Sarici
Kubra Sarici
TLTerry Lee
Terry Lee
MHMajda Hadziahmetovic
Majda Hadziahmetovic